| Recruiting | A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Canc Colon Cancer, Rectal Cancer, Colorectal Cancer | Phase 2 | 2025-09-29 |
| Recruiting | Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guide Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM) | Phase 2 | 2025-08-08 |
| Recruiting | BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) Limited Stage Small Cell Lung Cancer | Phase 2 | 2025-03-11 |
| Withdrawn | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positiv Lung Cancer, Non-small Cell Lung Cancer | Phase 2 | 2023-11-01 |
| Recruiting | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma Multiple Myeloma | Phase 2 | 2023-10-23 |
| Recruiting | Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Me Breast Cancer | Phase 2 | 2023-07-24 |
| Completed | A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | 2021-05-03 |
| Completed | Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma Mantle Cell Lymphoma | Phase 2 | 2020-08-07 |
| Terminated | A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) Chronic Graft-versus-host-disease | Phase 2 | 2020-06-05 |
| Terminated | A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Le Leukemia, Myeloid, Acute | Phase 2 | 2020-06-03 |
| Withdrawn | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosp Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myelodysplastic Syndrome Acute Myeloid Leukemia | Phase 1 | 2020-04-13 |
| Completed | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a Non-Small Cell Lung Cancer, Solid Tumor | Phase 2 | 2019-08-30 |
| Completed | Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progres Hodgkin Lymphoma | Phase 2 | 2018-05-23 |
| Terminated | Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Live Neuroendocrine Tumors, Gastrointestinal Neoplasms, Carcinoid Tumors | Phase 2 | 2017-07-28 |
| Terminated | Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma | Phase 2 | 2017-01-12 |
| Completed | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alte Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon | Phase 2 | 2016-09-28 |
| Completed | Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myelom Multiple Myeloma | Phase 2 | 2016-09-21 |
| Terminated | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Mali Small Cell Lung Cancer, Ovarian Cancer | Phase 1 | 2016-03-23 |
| Withdrawn | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma Melanoma | Phase 1 | 2015-12-01 |
| Completed | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Glioblastoma Multiforme, Gliosarcoma, Colorectal Cancer | Phase 1 | 2015-09-22 |
| Completed | Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers Neuroendocrine Cancer | Phase 2 | 2015-07-15 |
| Completed | Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients Metastatic Breast Cancer | — | 2015-05-13 |
| Completed | Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Gastroesophageal Cancer | Phase 2 | 2015-05-05 |
| Withdrawn | iCORE: Collaborative Orthopedics Outcomes Registry Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee | — | 2015-04-01 |
| Terminated | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory M Multiple Myeloma | Phase 2 | 2015-01-01 |
| Completed | Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Can Breast Cancer | Phase 2 | 2014-12-18 |
| Withdrawn | Sarah Cannon Outcomes Registry Oncology | — | 2014-12-01 |
| Completed | Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer Prostate Cancer | Phase 1 | 2014-10-01 |
| Completed | Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myelo Multiple Myeloma | Phase 2 | 2014-09-01 |
| Terminated | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma Primary Central Nervous System Lymphoma | Phase 2 | 2014-07-01 |
| Completed | Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metast Colorectal Neoplasms | Phase 2 | 2014-07-01 |
| Terminated | Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Me Metastatic Breast Cancer With Intracranial Metastases | Phase 2 | 2014-05-01 |
| Withdrawn | Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treat Advanced Prostate Cancer | Phase 2 | 2014-04-01 |
| Completed | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor Metastatic Breast Cancer | Phase 2 | 2014-03-01 |
| Completed | Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erl Non Small Cell Lung Cancer | Phase 2 | 2014-03-01 |
| Completed | Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2013-09-01 |
| Completed | Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lun Non Squamous Non Small Cell Lung Cancer | Phase 2 | 2013-07-01 |
| Completed | Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia | Phase 2 | 2013-07-01 |
| Completed | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 1 | 2013-05-01 |
| Terminated | Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric HER2 Positive Esophagogastric Cancer | Phase 2 | 2013-02-01 |
| Completed | 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Can Rectal Cancer | Phase 2 | 2013-01-01 |
| Completed | Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer Non Small Cell Lung Cancer | — | 2012-10-01 |
| Completed | Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Wh Diffuse Large B-Cell Lymphoma | Phase 2 | 2012-10-01 |
| Completed | Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Malignant Solid Tumour, Gastroesophageal Cancer | Phase 1 / Phase 2 | 2012-07-01 |
| Completed | Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HE HER2 Negative Breast Cancer | Phase 2 | 2012-06-01 |
| Completed | A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Can Colorectal Cancer | Phase 2 | 2012-01-01 |
| Completed | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma Multiple Myeloma | Phase 1 / Phase 2 | 2011-12-01 |
| Completed | Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor Gastrointestinal Stromal Tumor | Phase 2 | 2011-12-01 |
| Completed | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multifor Glioblastoma Multiforme | Phase 1 / Phase 2 | 2011-12-01 |
| Completed | Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chem Metastatic Breast Cancer | Phase 2 | 2011-09-23 |
| Completed | Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors Malignant Solid Tumour | Phase 1 | 2011-04-01 |
| Completed | Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer Breast Cancer | N/A | 2011-01-01 |
| Completed | FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Onl Colorectal Cancer | Phase 2 | 2010-12-01 |
| Completed | A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumo Metastatic or Unresectable Solid Tumor Malignancy | Phase 1 | 2010-11-01 |
| Completed | Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer Metastatic Colorectal Cancer | Phase 1 | 2010-07-01 |
| Completed | Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | 2010-07-01 |
| Completed | Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC Non-Small-Cell Lung Cancer | Phase 2 | 2010-06-01 |
| Completed | A Retrospective Cohort Study of Infusion Reactions Due to Vectibix Infusion Reaction | — | 2010-06-01 |
| Completed | Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatm Multiple Myeloma | Phase 2 | 2010-05-01 |
| Terminated | SCRI Tissue Testing Registry Melanoma, Myelodysplastic Syndrome, Multiple Myeloma | — | 2010-05-01 |
| Completed | Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Neuroendocrine Carcinoma | Phase 2 | 2010-05-01 |
| Completed | Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma Lymphoma | Phase 2 | 2010-03-01 |
| Completed | Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma Metastatic Melanoma | Phase 2 | 2010-02-01 |
| Completed | Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer Metastatic Breast Cancer | Phase 2 | 2010-02-01 |
| Terminated | Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial M Intracranial Meningioma | Phase 2 | 2010-01-01 |
| Completed | Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Non Small Cell Lung Cancer | Phase 2 | 2010-01-01 |
| Terminated | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarc Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma | Phase 1 / Phase 2 | 2010-01-01 |
| Completed | Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer Metastatic Breast Cancer | Phase 1 / Phase 2 | 2009-12-01 |
| Completed | A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cance Extensive-Stage Small Cell Lung Cancer | Phase 2 | 2009-12-01 |
| Terminated | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC Non-Small Cell Lung Cancer | Phase 2 | 2009-08-01 |
| Completed | Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer Metastatic Breast Cancer | Phase 2 | 2009-07-01 |
| Completed | Trial of Poor Performance Status Patients (ToPPS) Non Small Cell Lung Cancer | Phase 2 | 2009-06-01 |
| Completed | Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Canc Non Small Cell Lung Cancer | Phase 2 | 2009-06-01 |
| Completed | Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer Breast Cancer | Phase 1 / Phase 2 | 2009-06-01 |
| Completed | Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma Renal Cell Carcinoma | — | 2009-05-01 |
| Completed | Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer Unknown Primary Cancer | — | 2009-05-01 |
| Completed | Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer Breast Cancer | Phase 2 | 2009-04-01 |
| Completed | Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer Metastatic Breast Cancer | Phase 1 / Phase 2 | 2009-03-01 |
| Completed | Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas Metastatic Pancreatic Cancer | Phase 2 | 2009-02-01 |
| Completed | Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer Breast Cancer | Phase 2 | 2009-02-01 |
| Completed | RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM Glioblastoma Multiforme | Phase 2 | 2009-01-01 |
| Completed | A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer Breast Cancer | Phase 3 | 2008-12-01 |
| Completed | Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer Metastatic Breast Cancer | — | 2008-11-01 |
| Completed | PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors Refractory Solid Tumors | Phase 1 | 2008-10-01 |
| Completed | Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma Renal Cell Carcinoma | Phase 2 | 2008-09-01 |
| Completed | Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer Non-Small Cell Lung Cancer | Phase 2 | 2008-09-01 |
| Completed | Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site Carcinoma | Phase 2 | 2008-08-01 |
| Completed | Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer Small Cell Lung Cancer | Phase 2 | 2008-06-01 |
| Completed | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma Mantle Cell Lymphoma | Phase 1 / Phase 2 | 2008-06-01 |
| Completed | LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients Breast Cancer | Phase 1 | 2008-05-01 |
| Completed | Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer Breast Cancer | Phase 2 | 2008-04-01 |
| Completed | Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib Non-Small Cell Lung Cancer | Phase 2 | 2008-03-01 |
| Completed | Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors Refractory Malignancy | Phase 1 | 2008-02-01 |
| Completed | Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) Non-Small Cell Lung Cancer | Phase 2 | 2008-02-01 |
| Completed | RAD001 Plus Bevacizumab in Metastatic Melanoma Metastatic Melanoma | Phase 2 | 2008-01-01 |
| Completed | LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Renal Cell Carcinoma | Phase 2 | 2008-01-01 |
| Terminated | LBH589 in Refractory Myelodysplastic Syndromes (MDS) Myelodysplastic Syndromes (MDS) | Phase 2 | 2008-01-01 |
| Completed | Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting Gastrointestinal Stromal Tumors | — | 2008-01-01 |
| Completed | Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leuk Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | 2008-01-01 |
| Completed | Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC Non-Small Cell Lung Cancer | Phase 2 | 2007-12-01 |
| Completed | LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors Solid Tumors | Phase 1 | 2007-12-01 |
| Completed | CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas Pancreatic Cancer | Phase 1 / Phase 2 | 2007-11-01 |
| Completed | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients Multiple Myeloma | Phase 1 / Phase 2 | 2007-11-01 |
| Terminated | LBH589 and Gemcitabine in the Treatment of Solid Tumors Solid Tumors | Phase 1 | 2007-11-01 |
| Completed | Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer Breast Cancer | N/A | 2007-05-01 |
| Completed | Vinflunine in Hormone Refractory Prostate Cancer (HRPC) Prostate Cancer | Phase 2 | 2007-05-01 |
| Completed | Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme Glioblastoma Multiforme | Phase 2 | 2007-04-01 |
| Completed | First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC Lung Cancer | Phase 2 | 2007-03-01 |
| Completed | Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer Esophageal Cancer | Phase 2 | 2007-02-01 |
| Completed | High-dose Bevacizumab in Advanced Renal Carcinoma Patients Renal Cancer, Kidney Cancer | Phase 2 | 2007-02-01 |
| Completed | Treatment of Head & Neck Cancer With Chemotherapy and Radiation Head and Neck Cancer | Phase 2 | 2006-12-01 |
| Completed | Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cance Kidney Cancer | Phase 1 / Phase 2 | 2006-12-01 |
| Terminated | Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer Lung Cancer | Phase 2 | 2006-11-01 |
| Completed | Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Breast Cancer, Breast Neoplasms | Phase 2 | 2006-11-01 |
| Completed | Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer Breast Cancer | Phase 2 | 2006-10-01 |
| Completed | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Canc Ovarian Cancer | Phase 2 | 2006-10-01 |
| Completed | Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Neoplasm, Unknown Primary | Phase 2 | 2006-07-01 |
| Completed | Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma Kidney Cancer | Phase 2 | 2006-05-01 |
| Completed | Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer Carcinoma, Small Cell | Phase 2 | 2006-03-01 |
| Completed | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Rectal Cancer, Cancer of the Rectum, Colorectal Cancer | Phase 2 | 2006-03-01 |
| Completed | Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies Ovarian Cancer, Endometrial Cancer, Cervical Cancer | Phase 1 | 2006-03-01 |
| Completed | Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Carcinoma, Small Cell Lung, Lung Cancer | Phase 2 | 2006-03-01 |
| Completed | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Carcinoma, Small Cell Lung | Phase 2 | 2006-02-01 |
| Completed | Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer Breast Cancer | Phase 2 | 2006-02-01 |
| Completed | Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer Small Cell Lung Cancer, Carcinoma, Small Cell | Phase 2 | 2006-02-01 |
| Completed | Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Carcinoma, Small Cell, Lung Cancer | Phase 2 | 2006-01-01 |
| Completed | Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic B Breast Neoplasms, Breast Cancer | Phase 2 | 2006-01-01 |
| Completed | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma Lymphoma, Follicular | Phase 2 | 2005-09-01 |
| Completed | Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Breast Cancer | Phase 2 | 2005-09-01 |
| Completed | Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer Lung Cancer | Phase 2 | 2005-07-01 |
| Completed | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer Colon Cancer | Phase 2 | 2005-07-01 |
| Completed | Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer Breast Cancer | Phase 2 | 2005-05-01 |
| Completed | Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer Lung Cancer | Phase 2 | 2005-05-01 |
| Completed | PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies Refractory Malignancy, Advanced Malignancies | Phase 1 | 2004-10-01 |
| Completed | Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site Neoplasms, Unknown Primary | Phase 2 | 2004-09-01 |
| Completed | Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer Prostate Cancer | Phase 2 | 2004-08-01 |
| Completed | Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors Refractory Malignancy, Solid Tumors | Phase 1 | 2004-07-01 |
| Completed | Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung C Lung Cancer | Phase 3 | 2004-06-01 |
| Completed | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | 2004-06-01 |
| Completed | Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer Prostate Cancer | Phase 2 | 2004-05-01 |
| Completed | Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma Multiple Myeloma | Phase 2 | 2004-05-01 |
| Completed | Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site Neoplasms, Unknown Primary | Phase 2 | 2004-04-01 |
| Completed | Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer Esophagus Cancer | Phase 1 / Phase 2 | 2004-04-01 |
| Completed | Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Lung Cancer | Phase 2 | 2004-04-01 |
| Completed | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | 2004-04-01 |
| Completed | Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer Breast Cancer | Phase 2 | 2004-03-01 |
| Completed | Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer Colon Cancer | Phase 2 | 2004-01-01 |
| Completed | Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer Breast Cancer | Phase 2 | 2003-11-01 |
| Completed | Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cance Head and Neck Cancer | Phase 2 | 2003-10-01 |
| Completed | Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Non-Hodgkins Lymphoma | Phase 2 | 2003-10-01 |
| Completed | Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site Neoplasms, Unknown Primary | Phase 3 | 2003-09-01 |
| Completed | Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer Lung Cancer | Phase 2 | 2003-08-01 |
| Completed | Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Sol Cancer | Phase 1 | 2003-05-01 |
| Completed | Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Non-Hodgkins Lymphoma | Phase 2 | 2003-04-01 |
| Completed | Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer Lung Cancer | Phase 2 | 2003-03-01 |
| Completed | OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma Kidney Cancer | Phase 2 | 2003-02-01 |
| Completed | Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer Lung Cancer | Phase 2 | 2002-09-01 |
| Completed | Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer Lung Cancer | Phase 2 | 2002-09-01 |
| Completed | Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer Lung Cancer | Phase 2 | 2002-08-01 |
| Completed | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin' Non-Hodgkins Lymphoma | Phase 2 | 2002-04-01 |
| Completed | Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma Multiple Myeloma | Phase 2 | 2002-03-01 |
| Completed | Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer Breast Cancer | Phase 3 | 2002-03-01 |
| Completed | Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors Cancer | Phase 1 | 2002-02-01 |
| Completed | Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Ovary Cancer | Phase 2 | 2002-02-01 |
| Completed | Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Non-Hodgkins Lymphoma | Phase 2 | 2002-01-01 |
| Completed | Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer Breast Cancer | Phase 2 | 2001-11-01 |
| Terminated | Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer Breast Cancer | Phase 2 | 2001-09-01 |
| Completed | Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Lung Cancer | Phase 2 | 2001-08-01 |
| Completed | Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 Breast Cancer | Phase 2 | 2001-07-01 |
| Terminated | Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer Breast Cancer | Phase 2 | 2001-04-01 |
| Completed | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Canc Breast Cancer | Phase 2 | 2001-04-01 |
| Completed | Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer Breast Cancer | Phase 2 | 2001-02-01 |
| Completed | Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer Lung Cancer | Phase 2 | 2000-11-01 |
| Completed | Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer Lung Cancer | Phase 2 | 2000-11-01 |
| Completed | Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carc Prostate Cancer | Phase 2 | 2000-08-01 |
| Completed | Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer Esophagus Cancer | Phase 2 | 1999-10-01 |
| Completed | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcino Neuroendocrine Carcinoma | Phase 2 | 1998-12-01 |
| Withdrawn | A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease Chronic Graft-Versus-Host Disease | Phase 2 | — |